T1	Participants 668 746	patients (aged 18-75 years) with, or with high risk of, coronary heart disease
T2	Participants 926 977	Patients and investigators were masked to treatment
T3	Participants 1489 1595	189 patients were screened and 130 randomly assigned to placebo (66 patients) or dalcetrapib (64 patients)
T4	Participants 2103 2135	was not different between groups
T5	Participants 2375 2433	the frequency of adverse events was similar between groups
